Skip to main navigation
AADI Bioscience AADI Bioscience AADI Bioscience
Navigation
Primary Navigation
  • Company
    • The Company
    • Leadership
    • Board of Directors
  • Our Science
    • mTOR Pathway
    • TSC1 & TSC2
    • nab Technology Platform
    • Publications and Abstracts
  • Our Medicine
    • Our Medicine
    • Advanced Malignant PEComa
    • Expanded Access
  • Pipeline
  • Patients
    • Patient Advocacy
    • Clinical Trials
  • Investors & News
  • Contact Us
    • General Contact
    • For Healthcare Professionals
    • Careers

Press Releases

Secondary Nav Investors & News
  • IR Overview
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Press Releases
  • Event Calendar
  • Presentations
    • Corporate Presentations
    • Scientific Presentations
  • Financial
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Forms
  • Governance
    • Governance Highlights
    • Committee Composition
  • IR Resources
    • Investor FAQ
    • Information Request
    • Email Alerts
    • IR Contacts

Keyword Search

Date Title PDF Version
03/28/23 Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
03/27/23 Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
03/26/23 Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
03/15/23 Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
03/03/23 Aadi Bioscience Announces Leadership Transition
02/22/23 Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference

Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts
 logo

17383 Sunset Blvd, Suite A250
Pacific Palisades, CA 90272

Footer Links - Top
  • Home
  • Leadership
  • Pipeline
  • Patients
  • Contact
  • Careers
Footer Links - Bottom
  • LinkedIn
  • Twitter
  • Terms & Conditions
  • Privacy